18:02 , Mar 13, 2019 |  BC Innovations  |  Distillery Therapeutics

Cocktails of AAV vectors encoding anti-HIV bNAbs to treat the infection

DISEASE CATEGORY: Infectious disease INDICATION: HIV/AIDS Non-human primate studies suggest cocktails of viral vectors encoding broadly neutralizing antibodies (bNAbs) against multiple HIV antigens could help treat HIV. The antibodies consist of variable regions of previously...
17:25 , Sep 14, 2018 |  BC Week In Review  |  Financial News

OncoResponse to move into clinic with $40M series B

OncoResponse Inc. (Houston, Texas) raised $40 million in a series B round led by RiverVest Venture Partners. Fellow new investors Qatar Investment Authority and Redmile Group participated, as did existing investors Alexandria Venture Investments, Arch...
22:22 , Sep 11, 2018 |  BC Extra  |  Financial News

OncoResponse to move into clinic with $40M series B

OncoResponse Inc. (Houston, Texas) raised $40 million in a series B round led by RiverVest Venture Partners. Fellow new investors Qatar Investment Authority and Redmile Group participated, as did existing investors Alexandria Venture Investments, Arch...
19:03 , Aug 17, 2017 |  BC Extra  |  Financial News

Atreca raises $35M in series B

Cancer immunotherapy company Atreca Inc. (Redwood City, Calif.) raised $35 million in a series B round co-led by new investor Wellington Management and an undisclosed U.S. healthcare fund, which is an existing investor. New investor...
07:00 , Aug 8, 2016 |  BioCentury  |  Emerging Company Profile

Interrogating immunity

OncoResponse Inc. is repurposing Theraclone Sciences Inc .'s I-STAR discovery platform to identify antibodies produced by exceptional responders to cancer immunotherapy. By tapping patients' natural immune responses, OncoResponse hopes to find novel immune targets and...
07:00 , Oct 12, 2015 |  BC Week In Review  |  Company News

University of Texas MD Anderson Cancer Center, Theraclone, OncoResponse deal

MD Anderson and Theraclone jointly launched cancer immunotherapy company OncoResponse. The newco closed a $9.5 million series A round co-led by MD Anderson. OncoResponse licensed Theraclone’s I-STAR antibody discovery platform to identify antibodies from exceptional...
01:19 , Oct 7, 2015 |  BC Extra  |  Financial News

MD Anderson, Theraclone launch OncoResponse

The University of Texas MD Anderson Cancer Center (Houston, Texas) and Theraclone Sciences Inc. (Seattle, Wash.) jointly launched cancer immunotherapy company OncoResponse Inc. (Houston, Texas). The newco closed a $9.5 million series A round co-led...
07:00 , May 4, 2015 |  BC Week In Review  |  Financial News

Theraclone completes venture financing

Theraclone Sciences Inc. , Seattle, Wash.   Business: Infectious, Inflammation   Date completed: 2015-04-30   Type: Venture financing   Raised: $3.1 million   Investors: Wellcome Trust ; existing investors   Note: Theraclone raised $3.1 million...
07:00 , Oct 2, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Unadapted, pathogenic simian/human immunodeficiency viruses (SHIVs) to model AIDS Nonhuman primate studies suggest that newly generated mucosally transmittable SHIV strains could help model AIDS and...
07:00 , Aug 4, 2014 |  BC Week In Review  |  Company News

Gilead, Theraclone deal

Theraclone granted Gilead exclusive rights to develop and commercialize products incorporating Theraclone’s preclinical broadly neutralizing HIV antibodies (bNAbs) for therapeutic applications. Theraclone received an undisclosed upfront payment and is eligible to receive undisclosed development and...